Clinical Trials Logo

Filter by:
NCT ID: NCT03553420 Recruiting - Clinical trials for Lipodystrophy Acquired

Registry for Patients With Lipodystrophy

ECLip Registry
Start date: December 16, 2017
Phase:
Study type: Observational [Patient Registry]

Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time. Sensible clinical and basic research into rare diseases such as lipodystrophy is only possible in multi-location networks with sufficient case numbers. Also, reliable information on the incidence of certain manifestation patterns, health status, etc. is of utmost importance for health care and health policy in this rare disease. Therefore, the European Consortium of Lipodystrophies (ECLip), an association of European experts on lipodystrophy, has launched a registry (OSSE) for lipodystrophies which is committed to help to improve the research conditions by consolidating this kind of information in a registry.

NCT ID: NCT03551145 Recruiting - Peri-Implantitis Clinical Trials

Patient Perception and Clinical Efficacy of a Collagen Matrix for the Treatment of Peri-implantitis

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

This is a multi-centre, randomized clinical trial which evaluates the efficiency of the collagen xenograft (Muco-Graft®) in comparison to the autologous connective tissue graft for the augmentation of keratinized mucosa and gaining hygienic access to the implants diagnosed with peri-implantitis.

NCT ID: NCT03548896 Recruiting - Dental Implant Clinical Trials

Ridge Regeneration in Three Wall Sockets

Start date: February 2016
Phase: N/A
Study type: Interventional

There is limited data regarding socket preservation in three wall defects and no enough evidence of implant placement in previously regenerated area with allograft. The aim of this randomized controlled clinical trial is to analyze and compare dimensional changes in extractions sites with buccal bone defects > 5 mm left untreated (simultaneous regeneration during implant placement) or treated using a mineralized allograft.

NCT ID: NCT03547973 Recruiting - Clinical trials for Metastatic Urothelial Cancer

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

TROPHY U-01
Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

NCT ID: NCT03543514 Recruiting - Colo-rectal Cancer Clinical Trials

PREHABILITATION RECTAL CANCER DURING ADJUVANCY VS BEFORE SURGERY

prehab-cspt
Start date: February 2, 2022
Phase:
Study type: Observational [Patient Registry]

Preoperative preparation protocol (prehabilitation) for patients diagnosed with colorectal cancer who need surgery. It consists of a change in the preoperative preparation. The patient is an active part of their preparation and the professionals help to achieve a better functional capacity to diminish morbidity and accelerate recovery. Three levels are controlled: - Physical: control and stimulation to exercise at home. - Nutrition: control and advice through homemade recipes. - Emotional: control of the level of haste or depression and advice of mindfullness techniques at home. If they need specific help they are derived from specialized professionals (rehabilitator, nutritionist / endocrinologist, psychologist).

NCT ID: NCT03540485 Recruiting - Autoimmune Diseases Clinical Trials

Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Start date: November 29, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I / II randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive Multiple Primary Sclerosis.

NCT ID: NCT03540290 Recruiting - Clinical trials for Peri-implant Mucositis

Treatment of Peri-implant Mucositis by Means of Implant Decontamination and Modification of the Implant Supported-prosthesis

Start date: January 10, 2017
Phase: N/A
Study type: Interventional

To test the modification of the implant prosthesis, in order to facilitate access to biofilm control, in combination with decontamination of the implant surface by means of an ultrasonic device with a plastic tip and plastic curettes, in comparison with the decontamination of the implant surface by means of an ultrasonic device with a plastic tip and plastic curettes, and no modification of the implant prosthesis.

NCT ID: NCT03535519 Recruiting - Clinical trials for Rheumatoid Arthritis

Rheumatoid Arthritis Response to Methotrexate

Start date: August 7, 2018
Phase:
Study type: Observational

Observational and prospective study of the ultrasound response to methotrexate in rheumatoid arthritis patients who started methotrexate

NCT ID: NCT03533933 Recruiting - Gingival Recession Clinical Trials

Clinical and Histomorphometric Analysis of Collagen Matrix Versus Connective Tissue Graft in Mucogingival Surgery in Orthodontic Patients

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

There are some orthodontics treatments that perform risk movements ,and a bone dehiscence may be expected. In that cases mucogingival surgery , such as connective tissue grafts, is necessary prior to tooth movement. The connective tissue graft in combination with coronal advanced flap is still considered the gold standard , although the use of porcine collagen matrix has obtained promising results for treatment of Miller class I and II recession defects. Most of the studies report clinical results after a connective tissue graft and there is no evidence about the type of attachment obtained after the graft is performed, a few articles have shown histological results. But, as a rule , a histological study is only performed under exceptional circumstances such as a dental fracture, untreatable decay, tooth extraction for orthodontic reasons, or other reasons. Most of the techniques results in the formation of a long junctional epithelium and connective tissue attachment with fibers parallel to the root surface. Animals studies have shown a shorter epithelium and a larger new cementum formation after the use of the collagen matrix.

NCT ID: NCT03529448 Recruiting - Glioblastoma Clinical Trials

TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

GEINOCANN
Start date: August 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Glioblastoma is the primary brain tumour with the worst prognosis: median survival is only 12 months despite the use of the most advanced treatments. In the past 10 years, survival in the treatment of this disease has not advanced significantly, with the postoperative standard being the administration of chemoradiotherapy with temozolomide, followed by 6 cycles of sequential chemotherapy with temozolomide. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models. THC and CBD have a wide variety of biological effects by binding with and activating the type 1 and type 2 cannabinoid receptors (CB1 expressed in certain neuronal areas of the brain and CB2 expressed in the immune system and in glial cells). The activation of these receptors initiates a signalling pathway, called the endoplasmic reticulum stress response, which generates tumour cell autophagy by activating TRB3. Given these data, the Spanish Group for Neuro-oncology (GEINO) proposes developing a phase Ib, open-label, multicenter, intrapatient dose-escalation clinical trial to assess the safety profile of the THC+CBD combination at a 1:1 ratio, adding temozolomide and radiotherapy in patients with newly-diagnosed glioblastoma. The number of patients to be recruited is 30 over 6 months at 8 sites specialising in neuro-oncology.